Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer

Trial Profile

Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2018

At a glance

  • Drugs Pembrolizumab (Primary) ; Cisplatin
  • Indications Bladder cancer
  • Focus Adverse reactions
  • Acronyms PCR-MIB
  • Most Recent Events

    • 16 Feb 2018 Trial design presented at the 2018 Genitourinary Cancers Symposium.
    • 10 Jun 2017 Biomarkers information updated
    • 11 Oct 2016 Trial design presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top